Army researchers collaborate on universal antibody test for COVID-19

15-Oct-2020 11:15 AM EDT, by U.S. ARMY Research Laboratory

Newswise — ADELPHI, Md. -- Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster, easier and less expensive to use on a large scale. Their method holds promise for accurately identifying potential donors who have the best chance of helping infected patients through convalescent plasma therapy.

Dr. Jimmy Gollihar, biochemist and biotechnologist for the U.S. Army Combat Capabilities Development Command's Army Research Laboratory at CCDC ARL South in Austin, Texas, and chief technology officer of the Bioindustrial Manufacturing Innovation Institute, in collaboration with Dr. John Dye at the U.S. Army Medical Research Institute of Infectious Diseases, or USAMRIID, and collaborators at Houston Methodist, Pennsylvania State University and the University of Texas at Austin, sought to find alternatives to measuring virus neutralization, or VN, titers. These titers are the gold standard of COVID-19 antibody testing, as VN antibodies in the blood have been shown to correlate with levels of protective immunity.

According to the researchers, this kind of antibody testing is not widely available as it is technically complex and requires days to set up, run and interpret. Thus, the team looked to another type of test, called enzyme-linked immunosorbent assays, or ELISAs.

According to Gollihar, ELISAs are standard quantitative tests used to measure the amount of antibody to a particular antigen in a given sample.

"ELISAs are standard assays that can be performed in almost any academic or medical laboratory," Gollihar said. "This is important in emergency care centers treating critically ill patients. The assays can also be used for serological monitoring of the disease."

Specifically, scientists looked at the relationship of anti-spike ectodomain, or ECD, and anti-receptor binding domain, or RBD, antibody titers in the bloodstream. The spike ECD and RBD proteins are components of the much-talked-about spike protein made by SARS-CoV-2 and are critical to how the virus enters the body, spreads and causes COVID-19 disease.

Gollihar's specific roles included coordinating the plasma sample delivery from Houston Methodist, scaling production and purification of the antigens, and setting up the collaboration with USAMRIID for live virus neutralization testing under biocontainment conditions. He also helped transition the ELISA assay to Houston Methodist's automation team.Dye and his team performed neutralization assays on all the specimens in a Biosafety Level 3 laboratory at USAMRIID. Their work determined that the relative amount of antibody in the bloodstream of COVID-19 patients is linked to their ability to control viral infection; essentially, the more severe the disease, the higher the levels of neutralizing antibody present. This information provides potential benchmarks for a clinical product for convalescent plasma treatment studies; it could also be used to assess how well a vaccine recipient may respond to a subsequent infection.

The researchers found that the ELISA tests had an 80 percent or greater probability of predicting VN titers at or above the Food and Drug Administration-recommended levels for COVID-19 convalescent plasma.

"In all, we discovered that high titer ELISAs correlate well to virus neutralization and can be used as a surrogate for screening convalescent plasma," Gollihar said.

In addition, the researchers found that convalescent donors maintain high levels of immunity over the course of many weeks, and that frequent plasma donations did not cause a significant decrease in antibody or virus neutralization levels.

Perhaps most surprising, the researchers said, is that they identified 27 individuals from the surveillance cohort with high enough antibody titers to indicate that some asymptomatic individuals may have plasma suitable for therapeutic use and may have a degree of relative immunity against SARS-CoV-2.

"This collaboration between the Army, Houston Methodist and our partners in academia shows the incredible diversity of complementary capabilities we can deploy in responding to a worldwide pandemic," Dye said.

The team's findings are described in a paper titled, "Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization," featured in the Journal of Clinical Investigation.

###

Funding from the National Institutes of Health, the Fondren Foundation, the National Institute of Allergy and Infectious Diseases, the Army Research Office, Houston Methodist Hospital, Houston Methodist Infectious Diseases Research Fund, Houston Methodist Research Institute and seed funding from the Huck Institutes of the Life Sciences for the studies at Penn State, together with the Huck Distinguished Chair in Global Health award supported this study. The CARES Act with programmatic oversight from the Military Infectious Diseases Research Program also supported this work.

SEE ORIGINAL STUDY

MEDIA CONTACT
Register for reporter access to contact details
CITATIONS

Journal of Clinical Investigation




Filters close

Showing results

110 of 3718
Released: 20-Oct-2020 5:40 PM EDT
Nearly a Quarter of New York City Transit Workers Report Having Had COVID-19
New York University

A survey of New York City’s bus and subway workers finds that 24 percent report having contracted COVID-19 and 90 percent fear getting sick at work. The pilot study, conducted by researchers at NYU School of Global Public Health, in coordination with the Transport Workers Union (TWU) Local 100, helps document the toll the pandemic has taken on the physical and mental health of essential workers.

Released: 20-Oct-2020 5:10 PM EDT
Viral post claiming Dr. Anthony Fauci was indicted is entirely false
Newswise

A Facebook post from May that is newly gaining traction says that Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and the leading voice of experts in the coronavirus pandemic, has been indicted for treason. This claim is entirely false. Despite President Donald Trump calling him a "disaster," Fauci has not been indicted. There is no news coverage to support this claim, nor any original, credible documents or sources to corroborate it.

Released: 20-Oct-2020 4:10 PM EDT
Safety Considerations for Visiting Primary Care Doctors
Rutgers University-New Brunswick

The COVID-19 pandemic has left many people with chronic health conditions relying on telemedicine rather than seeing their doctor in person when necessary or putting off important visits entirely because they fear being infected. Ann M. Nguyen, an assistant research professor at Rutgers Center for State Health Policy at the Institute for Health, Health Care Policy and Aging Research, who recently published a paper on safety measures at physician offices, discusses what people should know about visiting their doctor and why putting off appointments that need to be done in person could lead to other health problems.

Released: 20-Oct-2020 3:50 PM EDT
New Jersey, Nation Surpass Halfway Employment Recovery Mark
Rutgers University-New Brunswick

New Jersey gained back half of the jobs lost due to the coronavirus pandemic but a wide disparity remains between higher-income professionals working at home and lower-wage support workers still bearing the brunt of the economic downturn that has gripped the nation, according to a new Rutgers report.

Newswise: 246364_web.jpg
Released: 20-Oct-2020 3:25 PM EDT
Effective ventilation may be a key factor in preventing the spread of COVID-19
ESTONIAN RESEARCH COUNCIL

During the first wave of COVID-19, which paralyzed the world in spring, it was initially thought that effective hand washing and 2-metre social distancing would help prevent the highly contagious virus.

Released: 20-Oct-2020 3:10 PM EDT
Researchers discovered the second 'key' used by the SARS-CoV-2 virus to enter into huma
University of Helsinki

To efficiently infect human cells, SARS-CoV-2, the virus that causes COVID-19, is able to use a receptor called Neuropilin-1, which is very abundant in many human tissues including the respiratory tract, blood vessels and neurons. The breakthrough discovery was made by a German-Finnish team of researchers led by neuroscientists Mika Simons ,Technical University of Munich, Germany and virologist Giuseppe Balistreri, University of Helsinki, Finland.

Released: 20-Oct-2020 2:50 PM EDT
Population currently sees coronavirus as the greatest health risk
BFR Federal Institute For Risk Assessment

Next on the list of concerns, though notably less frequently mentioned, are unhealthy or wrong diet as well as climate and environmental pollution - these were the most frequently mentioned concerns in February's survey. "The coronavirus pandemic dominates public perception", says BfR President Professor Dr. Dr. Andreas Hensel.

Released: 20-Oct-2020 2:45 PM EDT
Trump Mocked Biden for Saying He'll ‘Listen to the Scientists’
Newswise

U.S. President Donald Trump emphasized his stark contrast to his opponent Joe Biden in dealing with the COVID-19 pandemic when he mocked Biden for saying he'll "listen to scientists."

Released: 20-Oct-2020 2:35 PM EDT
Most psoriasis patients taking immunosuppressants survive COVID-19
National Institute for Health Research

Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19. According to the first findings from a global registry of psoriasis and COVID-19 patients, led by Guy's and St Thomas' clinicians, over 90% survive.

Newswise: Halloween Safety in the Coronavirus Era
Released: 20-Oct-2020 2:20 PM EDT
Halloween Safety in the Coronavirus Era
Cedars-Sinai

Halloween isn't going to be the same this year, but families can still have fun while reducing their risk of exposure to the virus that causes COVID-19 (coronavirus), says Priya Soni, MD, a Cedars-Sinai pediatric infectious disease specialist.


Showing results

110 of 3718

close
1.01238